Hydralazine hydrochloride
Common Name: |
Hydralazine hydrochloride |
IUPAC Name: |
phthalazin-1-ylhydrazine;hydrochloride |
Molecular Formula: |
C8H8N4 |
SMILES: |
C1=CC=C2C(=C1)C=NN=C2NN.Cl |
Inchi: |
1S/C8H8N4.ClH/c9-11-8-7-4-2-1-3-6(7)5-10-12-8;/h1-5H,9H2,(H,11,12);1H |
Inchi Key: |
ZUXNZUWOTSUBMN-UHFFFAOYSA-N |
Cas No: |
304-20-1 |
Name |
Value |
Lipinski Violations |
0 |
Ghose Violations |
0 |
Veber Violations |
0 |
Egan Violations |
0 |
Muegge Violations |
1 |
Name |
Value |
Molecular Weight (g/mol) |
196.64 |
Mass (g/mol) |
196.052 |
Molar Refractivity |
53.71 |
Net Charge |
1 |
HBD |
2 |
HBA |
3 |
Rt Bonds |
1 |
Rings |
2 |
TPSA |
63.83 |
Hetero Atoms |
4 |
Heavy Atoms |
13 |
Aromatic Heavy Atoms |
10 |
Melting Point (°C) |
273 |
Boiling Point (°C@760.00mm Hg) |
|
Vapor Pressure (mmHg@25.00 °C) |
|
Vapor Density (Air =1) |
|
Fraction Csp3 |
0.00 |
LogP |
0.915 |
iLOGP |
0.00 |
XLOGP3 |
1.80 |
WLOGP |
1.53 |
MLOGP |
1.49 |
ESOL Log S |
-2.70 |
ESOL Solubility (mg/ml) |
0.396 |
ESOL Solubility (mol/l) |
0.002 |
ESOL Class: esol_class |
Soluble |
Ali Log S |
-2.76 |
Ali Solubility (mg/ml) |
0.34 |
Ali Solubility (mol/l) |
0 |
Ali Class |
Soluble |
Silicos-IT LogSw |
-3.01 |
Silicos-IT Solubility (mg/ml) |
0.19 |
Silicos-IT Solubility (mol/l) |
0 |
Silicos-IT Class |
Soluble |
Name |
Value |
GI Absorption |
High |
BBB Permeable |
1 |
PgP Substrate |
0 |
Log Kp (cm/s) |
-6.22 |
Bioavailability Score |
0.55 |
Caco2 |
1 |
Human Intestinal Absorption |
1 |
Plasm Protein Binding |
0.601 |
CYP1A2 Inhibitor |
1 |
CYP2C19 Inhibitor |
0 |
CYP2C9 Inhibitor |
0 |
CYP2D6 inhibitor |
0 |
CYP3A4 inhibitor |
0 |
Ames mutagenesis |
1 |
Acute Oral Toxicity |
3.868 |
Carcinogenicity (Binary) |
0 |
Carcinogenicity (Trinary) |
Non-required |
Eye Irritation |
1 |
Hepatotoxicity |
1 |
Androgen Receptor Binding |
0 |
Aromatase Binding |
0 |
Estrogen Receptor Binding |
0 |
Glucocorticoid Receptor Binding |
0 |
Thyroid Receptor Binding |
1 |
BRCP inhibitor |
0 |
BSEP inhibitor |
0 |
OATP1B1 inhibitor |
1 |
OATP1B3 inhibitor |
1 |
OATP2B1 inhibitor |
0 |
OCT1 inhibitor |
0 |
OCT2 inhibitor |
1 |